Medical Cannabis Advocacy in South Asia During the 1990s

Legal landscape entering the 1990s

South Asia entered the 1990s under consolidating prohibitionist frameworks. India's Narcotic Drugs and Psychotropic Substances (NDPS) Act, passed in 1985, criminalized the production and sale of cannabis resin (charas) and flowering tops (ganja), but carved out a notable exception for leaves and seeds—the basis of bhang ^[1] Strong evidence. The Act implemented India's obligations under the 1961 Single Convention on Narcotic Drugs, which gave signatories 25 years to phase out non-medical cannabis use ^[2] Strong evidence.

Nepal had banned cannabis cultivation and sale in 1976 under international pressure, ending the legal hashish retail era of Kathmandu ^[3] Strong evidence. Pakistan formalized prohibition under the Control of Narcotic Substances Act in 1997 Weak / limited. Sri Lanka and Bangladesh maintained colonial-era restrictions, though both preserved limited traditional-medicine exemptions on paper.

The practical effect was clear: throughout the 1990s, medical cannabis advocacy in South Asia had almost no formal legal pathway. Where traditional medicine continued, it operated in legal gray zones, not under any modern medical-cannabis banner.

Traditional medicine systems as de facto continuity

What appeared as advocacy in the 1990s was more accurately continuity. Cannabis (vijaya, bhanga) has documented use in classical Ayurvedic texts including the Sharngadhara Samhita (13th–14th century) and Bhavaprakasha (16th century), where formulations like jatiphaladi churna include cannabis as an ingredient ^[4] Strong evidence. The Unani tradition similarly listed qinnab in its materia medica.

India's Central Council for Research in Ayurvedic Sciences (CCRAS) and the Department of AYUSH precursors maintained administrative permission for licensed Ayurvedic manufacturers to incorporate cannabis leaf in classical formulations throughout the 1990s, sourced through state excise channels in states like Uttar Pradesh and Rajasthan that retained bhang licensing. This was administrative precedent, not organized reform. There was no documented push to expand medical access, reschedule cannabis, or run clinical trials.

A widespread online claim holds that Indian Ayurvedic associations "lobbied for medical cannabis" during this period. We found no documented evidence of organized lobbying for expanded medical access during the 1990s No data. Documented efforts instead focused on preserving existing traditional-medicine exemptions under the NDPS Act, not creating new pathways.

Academic and international context

The closest thing to organized critique came from a small number of researchers and harm-reduction voices. Indian researchers working through the late 1980s and 1990s—particularly associated with institutions like the National Institute of Mental Health and Neuro-Sciences (NIMHANS) in Bangalore—published on cannabis use patterns and questioned the public-health framing that underpinned the NDPS Act, though this work did not coalesce into a domestic advocacy movement Weak / limited.

The Indian Hemp Drugs Commission Report of 1894–95, often cited in modern reform arguments, was indeed rediscovered and recirculated by academics during the 1990s; its finding that moderate cannabis use caused little harm became a reference point for later reformers ^[5] Strong evidence. However, this recirculation did not generate an organized 1990s movement.

Internationally, the 1990s saw the founding of the International Association for Cannabinoid Medicines (1997) in Europe and California's Proposition 215 in 1996 ^[6] Strong evidence. South Asian journalists and academics noted these developments, but they did not translate into domestic advocacy organizations during the decade itself.

Myths about 1990s South Asian cannabis advocacy

Several myths about the period circulate online and warrant direct correction.

Myth: "India had a strong medical cannabis movement in the 1990s." It did not. India had administrative continuity in traditional medicine and isolated academic critique. The first organized Indian medical cannabis advocacy organizations—such as the Great Legalisation Movement India—emerged in the 2010s, not the 1990s Weak / limited.

Myth: "Nepal quietly tolerated medical cannabis throughout the 1990s." Nepal's 1976 ban was enforced inconsistently, but there was no medical-cannabis carve-out and no organized medical advocacy. Continued religious use during festivals like Maha Shivaratri at Pashupatinath is cultural-religious practice, not medical advocacy Anecdote.

Myth: "Ayurvedic doctors openly prescribed cannabis medicines." Individual practitioners occasionally prescribed cannabis-based formulations where state regulations permitted, but this practice was legally uncertain and rare. Most Ayurvedic practitioners avoided it. Licensed manufacturers could produce classical formulations, but prescription-level medical advocacy did not materialize Weak / limited.

The factual summary: the 1990s in South Asia were a legally constrained decade for cannabis reform. Major policy developments—India's 2017 reclassification proposals, Nepal's 2020 parliamentary motion to legalize, and Thailand's 2018 medical legalization—all occurred two decades later.

Why this distinction matters for understanding modern reform

Accurately characterizing the 1990s clarifies where contemporary South Asian cannabis reform actually originates. It is not the resumption of a suppressed 1990s movement. It is a new movement, drawing on rediscovered colonial-era documents like the Indian Hemp Drugs Commission Report and on the global wave of medical legalization that began with California in 1996 and accelerated in the 2010s across multiple continents.

The traditional-medicine infrastructure that survived the 1990s—bhang licensing in some Indian states, Ayurvedic pharmacopeial recognition, and cultural continuity of cannabis use—forms the substrate on which any future South Asian medical cannabis framework might be built. But the organized advocacy itself is a 21st-century development.

Mischaracterizing the 1990s as a hidden era of reform does a disservice to the people engaged in actual advocacy today. Modern reformers deserve credit for building a new movement, not for reviving a phantom one.

Sources

How this page was made

Related

• 1961 Single Convention on Narcotic Drugs — The UN treaty that unified international drug control and shaped cannabis prohibition glob...
• Cannabis Activism in East Asia During the 1990s — A historical examination of why East Asia had no organized cannabis activism in the 1990s.
• Cannabis in South Asian Music of the 1980s — Cannabis in South Asian song through devotion, law, and regional politics during the 1980s...
• First Medical Cannabis Dispensaries in California — How AIDS activism and buyers' clubs became the first legal cannabis dispensaries in Americ...
• Medical Cannabis Advocacy in Australia and New Zealand During the 1990s — How patient advocacy and harm reduction shaped the 1990s medical cannabis conversation in...
• Medical Cannabis Advocacy in South Asia During the 1930s — India's defence of cannabis at the League of Nations, revenue interests, and how modern my...
• UN Drug Treaties and Cannabis — Three UN treaties control cannabis globally; legalization exists despite treaty language f...